🏛️ Verified NIH Record • Updated 2026-03-20

Obe-cel in Refractory Progressive Forms of Multiple Sclerosis (NCT07139743)

A Single-arm, Open-label, Phase I Study to Determine the Safety, Tolerability, and Preliminary Efficacy of Obe-cel in Participants With Refractory Progressive Forms of Multiple Sclerosis

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Autolus Limited

🩺 Plain-English Summary (8th-Grade Level)

The main purpose of this study is to evaluate if obe-cel is safe or causes any side effects in adults with refractory progressive MS. The study also plans to assess if obe-cel can show early signs of efficacy in MS. The trial includes only 1 group of participants (single-arm). The study population comprises participants with progressive forms of MS, not responsive to highly effective therapies. Upon confirmation of study eligibility, participants will receive chemotherapy (used here for lymphodepletion) over 1 to 3 days in preparation for receiving a single obe-cel infusion. Participants will be checked closely in the 28 days following obe-cel treatment. After this, participants will be monitored to evaluate safety and efficacy up to 24 months.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (7 items).

Location: Stanford University — Redwood City, California

Age range: 18 Years to 60 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Any medications prohibited by the protocol.
  • Highly active multiple sclerosis.
  • Diagnosis of another autoimmune central nervous system condition.
  • Active or uncontrolled fungal, bacterial, viral infection.
  • History of malignant neoplasms unless disease-free for at least 24 months.
  • History of heart, lung, kidney, liver transplant or hematopoietic stem cell transplant.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (7 Sites)

  • Stanford University — Redwood City, California
  • Hospital Universitario Vall d'Hebron - PPDS — Barcelona,
  • Hospital Universitari i Politecnic La Fe de Valencia — Valencia,
  • Addenbrooke's Hospital — Cambridge,
  • Western General Hospital Edinburgh - PPDSE Edinburgh — Edinburgh,
  • The National Hospital for Neurology & Neurosurgery — London,
  • Royal Hallamshire Hospital — Sheffield,

📞 Contact the Study Coordinator

Phone: +44 (0)203 911 4385

Email: clinicaltrials@autolus.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
  • 💵 Compensation indicated: Upon confirmation of study eligibility, participants will receive chemotherapy (used here for lymphodepletion) over 1 to 3 days in preparation for receiving a single obe-cel infusion.

More studies in Progressive Multiple Sclerosis

Explore by condition: All Progressive Multiple Sclerosis clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗